Status:
COMPLETED
Melatonin Receptor Agonist and Peripheral Biological Markers
Lead Sponsor:
National Science and Technology Council, Taiwan
Conditions:
Insomnia
Eligibility:
All Genders
20-80 years
Brief Summary
People who have insomnia typically co-occur with mental disorders, especially anxiety and depression. It has been documented that the melatonin phase in the depressed patients was reached with a delay...
Detailed Description
The higher values of circadian-clock-related proteins observed at day (brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein 1 and circadian locomoter output cycles protein kapu...
Eligibility Criteria
Inclusion
- Out-patients with primary insomnia and patients with major depressive disorder (MDD) and generalized anxiety disorder (GAD) with chief complaint of insomnia or a history of daytime complaint(s) associated with disturbed sleep. The diagnosis of MDD and GAD will be made made according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) Revised for at least 3 months.
- Patients are 20-80 years old, body mass index between 18 and 34, and without any ambulatory problems.
- Subject is a male or a post-menopausal female. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
- If they willing to give written informed consent and cooperative in this study. They are willing to write sleep diary.
- Subjective sleep latency greater than or equal to 45 minutes and a subjective total sleep time less than or equal to 6.5 hours per night for at least 3 nights during the week of the lead-in period.
- Habitual bedtime is between 8:30 PM and 12:00 AM.
Exclusion
- Known hypersensitivity to ramelteon or related compounds, including melatonin.
- Previously participated in a study involving ramelteon.
- Participated in any other investigational study, and/or took any investigational drug within 30 days or five half-lives prior to the first day of single-blind study medication, whichever is longer.
- Sleep schedule changes required by employment (eg, shift worker) within three months prior to the first day of single-blind study medication, or has flown across greater than three time zones within seven days prior to screening.
- Participated in a weight loss program or substantially altered exercise routine within 30 days prior to the first day of single blind study medication.
- Has ever had a history of seizures, sleep apnea, chronic obstructive pulmonary disease, restless leg syndrome, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
- History of substance use disorders, such drug addiction, drug abuse, alcohol abuse within the past 12 months, as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised and/or regularly consumes 4 or more alcoholic drinks per day.
- History of drug addiction or drug abuse within the past 12 months.
- Positive hepatitis panels.
Key Trial Info
Start Date :
January 11 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03432091
Start Date
January 11 2016
End Date
July 31 2019
Last Update
October 10 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.